GlassScriptPhysician profile
Winston E Watkins
NPI 1679595417
$2,295.78
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,911 · 2020: $354 · 2022: $30.99.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $675.03 | 2019-2020 | |
| Novo Nordisk INC | $404.00 | 2019-2020 | |
| Lilly USA, LLC | $326.35 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $219.45 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.00 | 2019-2020 | |
| Amarin Pharma, INC. | $114.26 | 2019-2020 | |
| Pfizer INC. | $63.11 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $61.94 | 2019-2020 | |
| Abbvie INC. | $51.52 | 2019 | |
| Boston Scientific Corporation | $46.52 | 2019-2020 | |
| Sanofi Pasteur INC. | $42.27 | 2019-2020 | |
| Baxter Healthcare | $30.99 | 2022 | |
| Genentech USA, INC. | $29.45 | 2019 | |
| Optinose US, INC. | $17.87 | 2020 | |
| Valeritas, INC. | $17.35 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $13.03 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.78 | 2019 | |
| Allergan, INC. | $11.78 | 2019 | |
| Merck Sharp & Dohme LLC | $11.08 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Winston Watkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.